Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

PURPOSE: New therapies are needed for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. This phase 1b, open-label trial evaluated two anti-CD20-based triplet combinations. METHODS: Patients with R/R follicular lymphoma (FL; n = 13) were treated with obinutuzumab, atezolizumab, and polatuzumab v...

Descripción completa

Detalles Bibliográficos
Autores principales: Topp, Max S., Eradat, Herbert, Florschütz, Axel, Hochhaus, Andreas, Wrobel, Tomasz, Walewski, Jan, Knopinska-Posluszny, Wanda, Kanate, Abraham S., Lech-Maranda, Ewa, Brunnberg, Uta, Chitra, Surya, Nielsen, Tina G., Sellam, Gila, Shivhare, Mahesh, Lossos, Izidore S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931830/
https://www.ncbi.nlm.nih.gov/pubmed/35182224
http://dx.doi.org/10.1007/s00432-021-03847-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931830/
https://www.ncbi.nlm.nih.gov/pubmed/35182224
http://dx.doi.org/10.1007/s00432-021-03847-5

Ejemplares similares